Acibadem Healthcare Group

acibadem.com.tr

The Acıbadem Healthcare Group is Turkey’s most valuable private healthcare organisation according to brand assessment results and the position the group has achieved in the sector. Today Acıbadem, with its 21 hospitals, 16 outpatient clinics, 3.500 doctors and 4.000 nurses, provides healthcare services with nearly 22.500 employees. The Group provides diagnosis and treatment services at certified healthcare standards with a qualified staff, advanced technology, modern infrastructure and JCI accreditation.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

QIAGEN LAUNCHES SYNDROMIC TEST FOR QIASTAT-DX DEVICE TO COMBAT GLOBAL MONKEYPOX HEALTH EMERGENCY

QIAGEN | August 16, 2022

news image

QIAGEN N.V. announced the launch of the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic test to differentiate between monkeypox and five other pathogens which cause similar symptoms. The new panel ­– currently for research use only comes in cartridge form to run on QIAGEN’s QIAstat-Dx automated syndromic testing devices. It tests for the two known forms of monkeypox virus herpes simplex virus 1 HSV2, human herpesvirus 6 (HH6), varicella-zoster virus and e...

Read More

Cell and Gene Therapy, Medical

BE THE MATCH BIOTHERAPIES® INTRODUCES CIBMTR® CRO SERVICES

Be The Match BioTherapies® | January 18, 2023

news image

On January 17, 2023, Be The Match BioTherapies, a company that provides solutions for organizations that develop and commercialize cell and gene therapies, introduced its offering of CIBMTR® clinical research organization services (CRO services), which significantly reduces the time needed to launch and execute high-impact clinical trials. These CRO services are the outcome of a collaboration between Be The Match BioTherapies and CIBMTR, resulting in expertise and access to ...

Read More

LABCORP'S CRO UNIT COVANCE DOUBLES DOWN ON CELL, GENE THERAPY OFFERINGS

FierceBiotech | January 21, 2020

news image

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get in on this burgeoning new trend. “These solutions are designed to reduce time and risk for sponsors at each phase and across the full continuum of their therapy development needs in one of the industry’s fastest-growing segments,” Covance, the CRO unit of diagnostics giant LabCorp, said in a statement. This follows the first CAR-T cell therapy approvals from Novartis ...

Read More

Industry Outlook

TRILINK BIOTECHNOLOGIES INTRODUCES LATEST MRNA CAPPING TECHNOLOGY: CLEANCAP® M6 ANALOG

Globenewswire | May 15, 2023

news image

TriLink BioTechnologies a Maravai LifeSciences company and global provider of life science reagents and services, has launched its newest cap analog, CleanCap® M6 . The latest CleanCap analog is expected to help developers and researchers maximize the impact of their mRNA therapeutics and vaccines while reducing overall manufacturing costs, bringing life-changing medicines to market faster. With the introduction of the CleanCap M6 technology, legacy capping methods like enzy...

Read More
news image

MedTech

QIAGEN LAUNCHES SYNDROMIC TEST FOR QIASTAT-DX DEVICE TO COMBAT GLOBAL MONKEYPOX HEALTH EMERGENCY

QIAGEN | August 16, 2022

QIAGEN N.V. announced the launch of the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic test to differentiate between monkeypox and five other pathogens which cause similar symptoms. The new panel ­– currently for research use only comes in cartridge form to run on QIAGEN’s QIAstat-Dx automated syndromic testing devices. It tests for the two known forms of monkeypox virus herpes simplex virus 1 HSV2, human herpesvirus 6 (HH6), varicella-zoster virus and e...

Read More
news image

Cell and Gene Therapy, Medical

BE THE MATCH BIOTHERAPIES® INTRODUCES CIBMTR® CRO SERVICES

Be The Match BioTherapies® | January 18, 2023

On January 17, 2023, Be The Match BioTherapies, a company that provides solutions for organizations that develop and commercialize cell and gene therapies, introduced its offering of CIBMTR® clinical research organization services (CRO services), which significantly reduces the time needed to launch and execute high-impact clinical trials. These CRO services are the outcome of a collaboration between Be The Match BioTherapies and CIBMTR, resulting in expertise and access to ...

Read More
news image

LABCORP'S CRO UNIT COVANCE DOUBLES DOWN ON CELL, GENE THERAPY OFFERINGS

FierceBiotech | January 21, 2020

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get in on this burgeoning new trend. “These solutions are designed to reduce time and risk for sponsors at each phase and across the full continuum of their therapy development needs in one of the industry’s fastest-growing segments,” Covance, the CRO unit of diagnostics giant LabCorp, said in a statement. This follows the first CAR-T cell therapy approvals from Novartis ...

Read More
news image

Industry Outlook

TRILINK BIOTECHNOLOGIES INTRODUCES LATEST MRNA CAPPING TECHNOLOGY: CLEANCAP® M6 ANALOG

Globenewswire | May 15, 2023

TriLink BioTechnologies a Maravai LifeSciences company and global provider of life science reagents and services, has launched its newest cap analog, CleanCap® M6 . The latest CleanCap analog is expected to help developers and researchers maximize the impact of their mRNA therapeutics and vaccines while reducing overall manufacturing costs, bringing life-changing medicines to market faster. With the introduction of the CleanCap M6 technology, legacy capping methods like enzy...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us